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Neisseria gonorrhoeae is an important cause of
sexually transmitted infections (STI) worldwide. The global
incidence of gonorrhoeae is approximately 62 million cases
per year. In developing countries it still remains a major
cause of infection. The importance of this disease is not
limited to its numerical frequency but also concerns the
complications it may cause and its ability to assist the
transmission of other STIs including HIV. 
By and large, infections in men are detected early
enough to prevent serious sequelae. In females, it causes
cervicitis, urethritis, pelvic inflammatory disease and
infertility and remains an asymptomatic (carrier) infection
in early stage.1 Therefore infection in females facilitates
dissemination of the disease in the community. Moreover
the frequency of pelvic inflammatory disease and infertility
is so common that early and appropriate treatment is
mandatory.
The prevalence of gonococcal infections varies
widely among communities and patient populations. In
Pakistan, incidence or prevalence data are not available to
give an accurate picture of the disease distribution.
However infection is common and treatment is expensive,
for primary as well as complicated cases.2
Given the scale of public health importance of
gonorrhea, selection of appropriate therapy is crucial. Early
treatment rapidly reduces infectivity and helps in disease
control. Therefore it is important that early, appropriate, and
effective therapy is provided to each case. The most useful
therapy against gonococcal infections should be a safe,
affordable and single dose regimen. Single dose oral
therapy is preferred to ensure compliance, and low cost and
to reduce risk of infections associated with parenteral
therapy.3
Unfortunately N. gonorrhoeae is one of the
community-acquired bacterial pathogens that are currently
causing problem of multidrug-resistance. High rate of
antimicrobial resistance against the conventional drugs such
as penicillins, tetracyclines and macrolides has limited their
use.4 Consequently, fluoroquinolones have become the most
appropriate and cost effective alternative. Globally
treatment of gonorrhoeae with this group of drugs is
complicated by exponential rise in antimicrobial resistance.
Quinolone resistant N. gonorrhoeae (QRNG) continued to
spread, in response to which center of diseases control and
prevention (CDC) recommended that quinolones should not
be used for the treatment of gonorrhea in areas with
increased prevalence of QRNG (>5%) in 2006.5
In Pakistan ciprofloxacin and ofloxacin are the most
frequently used antimicrobial agents to treat gonococcal
infections. However, previously Jabeen et al have reported
a high rate of quinolone resistance in clinical isolates from
the years 1992-2002.6 The association of in vitro resistance
with a high rate of treatment failure was a cause of major
concern. In recent years a further rise in resistance (76%,
unpublished AKUH laboratory data) excludes their use as
empirical agent in the management of gonococcal
infections.
Ceftriaxone resistance is not yet detected in local
gonococcal isolates and presently it remains the drug of
choice, though cost and parenteral mode of administration
limits its use. However it is highly desirable that public and
private sector laboratories should look for the emergence of
resistance against ceftriaxone as strains with reduced
susceptibility have been reported in the past.7
In search of alternative oral agents, recent studies
have evaluated efficacy of azithromycin, cefixime,
cefuroxime, cefpodoxime, levofloxacin and gatifloxacin.7
To date antimicrobial susceptibility of these drugs has not
been evaluated locally. Seeing that previously
recommended antibiotics have lost their efficacy, we stress
that it is vital to search for a suitable oral agent which can
effectively treat gonococcal infections. 
Finally, we recommend that to prevent further
dissemination of antimicrobial resistance and for an early
response, federal health department must take the lead and
with the collaboration of NIH, Islamabad and clinical
laboratories establish an infrastructure for the national
surveillance program to monitor emergence of
antimicrobial resistance not only for N. gonorrhoeae but
also for other bacterial pathogens. 
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